Cargando…

Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma

SIMPLE SUMMARY: Despite advances in both the surgical and medical management of oesophageal adenocarcinoma (OAC), overall prognosis remains poor, with less than 1 in 5 patients surviving more than 5 years from diagnosis. Patients suitable for treatment with curative intent receive pre-operative chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pickering, Oliver J., Breininger, Stella P., Underwood, Timothy J., Walters, Zoë S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392153/ https://www.ncbi.nlm.nih.gov/pubmed/34439236 http://dx.doi.org/10.3390/cancers13164084

Ejemplares similares

The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer
por: Lang, Cameron C. J., et al.
Publicado: (2022)

The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review
por: Murage, Nora Wangari, et al.
Publicado: (2023)

Fibroblasts derived from oesophageal adenocarcinoma differ in DNA methylation profile from normal oesophageal fibroblasts
por: Smith, Eric, et al.
Publicado: (2017)

GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma
por: Gotovac, Jovana R, et al.
Publicado: (2020)

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Izadi, Fereshteh, et al.
Publicado: (2021)

The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction
por: Curtis, Nathan J, et al.
Publicado: (2014)

Oestrogen Receptor Isoforms May Represent a Therapeutic Target in Oesophageal Adenocarcinoma
por: Due, Steven L., et al.
Publicado: (2022)

Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma
por: Manousopoulou, Antigoni, et al.
Publicado: (2018)

Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts
por: Sharpe, Benjamin P., et al.
Publicado: (2022)

Tonsillar metastasis of oesophageal adenocarcinoma
por: Struijs, Bram, et al.
Publicado: (2007)

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma
por: Noble, Fergus, et al.
Publicado: (2016)

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma
por: Matthews, LH McCormick, et al.
Publicado: (2015)

Histone Modifying Enzymes in Gynaecological Cancers
por: Ramarao-Milne, Priya, et al.
Publicado: (2021)

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma
por: McCormick Matthews, L H, et al.
Publicado: (2015)

Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes
por: Andreoli, Federico, et al.
Publicado: (2015)

Unlocking the potential of targeting histone-modifying enzymes for treating IBD and CRC
por: Liang, Bing, et al.
Publicado: (2023)

Targeting diagnostic interventions for oesophageal cancer
por: Hamilton, Willie, et al.
Publicado: (2023)

Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches
por: McCabe, Niamh H., et al.
Publicado: (2022)

MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications
por: Szczepanek, Joanna, et al.
Publicado: (2023)

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1
por: Garcia, Edwin, et al.
Publicado: (2016)

Co-Regulation of Histone-Modifying Enzymes in Cancer
por: Islam, Abul B. M. M. K., et al.
Publicado: (2011)

Ubiquitin Regulation: The Histone Modifying Enzyme′s Story
por: Wang, Jianlin, et al.
Publicado: (2018)

Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)

Spontaneous and inducible apoptosis in oesophageal adenocarcinoma
por: Raouf, A, et al.
Publicado: (2001)

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma
por: Underwood, Timothy J, et al.
Publicado: (2015)

Sex hormones and oesophageal adenocarcinoma: influence of childbearing?
por: Lagergren, J, et al.
Publicado: (2005)

HIstome—a relational knowledgebase of human histone proteins and histone modifying enzymes
por: Khare, Satyajeet P., et al.
Publicado: (2012)

Odontoid peg metastasis from an oesophageal adenocarcinoma.
por: Walsh, I. K., et al.
Publicado: (1993)

Passive smoking and risk of oesophageal and gastric adenocarcinomas
por: Duan, L, et al.
Publicado: (2009)

The future of combination immunotherapy in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2023)

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
por: Dermanis, Alexander A., et al.
Publicado: (2023)

Alterations in the Ca(2+) toolkit in oesophageal adenocarcinoma
por: Cutliffe, Alana L., et al.
Publicado: (2021)

The Oesophageal Cancer Multidisciplinary Team: Can Machine Learning Assist Decision-Making?
por: Thavanesan, Navamayooran, et al.
Publicado: (2023)

Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma
por: Donlon, Noel E, et al.
Publicado: (2022)

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1
por: Garcia, Edwin, et al.
Publicado: (2019)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
por: Turkington, Richard C, et al.
Publicado: (2019)

Sex-specific risk factor profile in oesophageal adenocarcinoma
por: Löfdahl, H E, et al.
Publicado: (2008)

Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas
por: Lindblad, M, et al.
Publicado: (2006)

Progressive silencing of p14ARF in oesophageal adenocarcinoma
por: Huang, Yinghui, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9q1nbhi9da9lbqt9m4h70ru8ku